Background
Methods
Clinical prostate specimens
Parameter | qRT-PCR (n = 270) | IHC (n = 239) | ||
---|---|---|---|---|
No. Pts | % | No. Pts | % | |
Age | ||||
≤ 55 | 15 | 5.6 | 12 | 5 |
56-65 | 81 | 30 | 72 | 30.1 |
66-75 | 138 | 51.1 | 122 | 51 |
> 75 | 36 | 13.3 | 33 | 13.8 |
Gleason-sp | ||||
2-6 | 109 | 40.4 | 87 | 36.4 |
7 | 129 | 47.8 | 123 | 51.5 |
Greater than 7 | 32 | 11.9 | 29 | 12.1 |
PSA (ng/ml) | ||||
10 or less | 155 | 57.6 | 133 | 55.9 |
10-20 | 74 | 27.5 | 69 | 29 |
Greater than 20 | 40 | 14.9 | 36 | 15.1 |
cT | ||||
cT2b or less | 248 | 92.2 | 219 | 92 |
cT3a or greater | 21 | 7.8 | 19 | 8 |
pT | ||||
pT2 or less | 135 | 50 | 115 | 48.1 |
pT3 or greater | 135 | 50 | 124 | 51.9 |
pNa
| ||||
pN0 | 236 | 95.2 | 209 | 95.4 |
pN1 or greater | 12 | 4.8 | 10 | 4.6 |
Margins | ||||
Negative | 137 | 50.7 | 116 | 48.5 |
Positive | 133 | 49.3 | 123 | 51.5 |
TMPRSS2/ERGb,c
| ||||
Negative | 92 | 34.1 | 105 | 48.8 |
Positive | 178 | 65.9 | 110 | 51.2 |
Gene expression analysis
Immunohistochemistry
Statistical analysis
Results
Gene expression profile of the IGF system in primary prostate cancer and its association with prognosis
Total cases | Biochemical progression | Clinical Progression | |||||||
---|---|---|---|---|---|---|---|---|---|
Parameter |
n
| Events (% BPFS) |
p-Univariate | HR (95% CI) |
p-Multivariate | Events (% PFS) |
p-Univariate | HR (95% CI) |
p-Multivariate |
Age | 0.165 | 0.379 | |||||||
≤ 55 | 15 | 5 (73.3) | 3 (79.4) | ||||||
56-65 | 81 | 43 (25.7) | 29 (50.1) | ||||||
66-75 | 138 | 58 (45.4) | 34 (69.8) | ||||||
> 75 | 36 | 18 (48.6) | 8 (59.2) | ||||||
Gleason-sp | < 0.0001 | 0.001 | < 0.0001 | 0.015 | |||||
2-6 | 109 | 35 (56.4) | 1 | 17 (77.3) | 1 | ||||
7 | 129 | 63 (29.8) | 2.94 (1.64-5.26) | < 0.0001 | 43 (57.4) | 3.03 (1.4-6.53) | 0.005 | ||
Greater than 7 | 32 | 25 (11.7) | 1.93 (1.18-3.16) | 0.008 | 14 (0) | 1.57 (0.83-2.96) | 0.163 | ||
PSA (ng/ml) | < 0.0001 | 0.011 | 0.09 | ||||||
10 or less | 155 | 57 (47.8) | 1 | 35 (68.6) | |||||
10-20 | 74 | 37 (39.2) | 2.12 (1.29-3.48) | 0.003 | 24 (53.6) | ||||
Greater than 20 | 40 | 29 (24.4) | 1.72 (1.03-2.88) | 0.036 | 15 (57.1) | ||||
cT | < 0.0001 | 0.013 | 0.029 | 1 | 0.002 | ||||
cT2b or less | 248 | 107 (43) | 1 | 66 (63.1) | 2.46 (1.38-4.4) | ||||
cT3a or greater | 21 | 16 (14.5) | 1.72 (1.03-3.67) | 8 (58.6) | |||||
pT | < 0.0001 | NS | 0.001 | NS | |||||
pT2 or less | 135 | 43 (57.4) | 25 (77.9) | ||||||
pT3 or greater | 135 | 80 (23) | 49 (48.4) | ||||||
pN | < 0.0001 | 0.043 | 0.2 | ||||||
pN0 | 236 | 104 (43) | 1 | 64 (63.6) | |||||
pN1 or greater | 12 | 11 (8.3) | 1.98 (1.02-3.84) | 5 (50.9) | |||||
Margins | < 0.0001 | 0.001 | < 0.0001 | 0.039 | |||||
Negative | 137 | 40 (56) | 1 | 24 (77) | 1 | ||||
Positive | 133 | 83 (21.4) | 2.14 (1.39-3.32) | 50 (41.6) | 1.74 (1.02-2.95) | ||||
TMPRSS2-ERG | 0.105 | 0.957 | |||||||
Negative | 92 | 49 (32.5) | 26 (63.9) | ||||||
Positive | 178 | 74 (45.2) | 48 (61.6) | ||||||
IGF-1R
| 0.046 | NS | 0.835 | ||||||
Low | 67 | 34 (45.3) | 17 (70.3) | ||||||
High | 203 | 89 (41.9) | 57 (61.4) | ||||||
INSR
| 0.987 | 0.632 | |||||||
Low | 66 | 29 (52.1) | 17 (69.9) | ||||||
High | 199 | 92 (38.3) | 57 (59.5) | ||||||
IGF-1
| < 0.0001 | 0.015 | 0.002 | NS | |||||
Low | 67 | 44 (18.2) | 1 | 26 (41.5) | |||||
High | 202 | 78 (48) | 0.60 (0.39-0.90) | 47 (68.6) | |||||
IGFBP-3
| 0.717 | 0.943 | |||||||
Low | 67 | 31 (45.9) | 17 (61.3) | ||||||
High | 203 | 92 (39.5) | 57 (62.9) |